B-CELL LYMPHOMA
Clinical trials for B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called LY4152199 in about 215 adults with certain types of blood cancer (like follicular lymphoma or diffuse large B-cell lymphoma) that have already been treated. The drug is designed to help the body's immune cells attack the cancer. The …
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill takes on tough blood cancers in first human trial
Disease control Not yet recruitingThis early-stage study tests a new tablet, FXS0683, in 228 adults with blood cancers like lymphoma or leukemia that returned or didn't respond to standard therapy. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will be clo…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
In-Body CAR-T: a new shot at fighting blood cancers?
Disease control Not yet recruitingThis early study tests a new treatment called U96 for people with B-cell leukemia or lymphoma that has come back or not responded to standard therapy. U96 is a gene therapy given as a single infusion that aims to create cancer-fighting CAR-T cells inside the patient's own body. T…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Which Pre-CAR-T chemo is safer? new trial aims to find out
Disease control Not yet recruitingThis trial tests whether bendamustine causes fewer severe side effects than the standard fludarabine/cyclophosphamide combination when given before CAR-T cell therapy for B-cell lymphoma. About 92 people will be randomly assigned to one of the two chemotherapy regimens. The main …
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could early antibiotic stop be safe for kids with cancer?
Disease control Not yet recruitingThis trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE4 • Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail aims to tackle tough blood cancers
Disease control Not yet recruitingThis study tests a new drug called NX-5948 (bexobrutideg) combined with other medicines (venetoclax, and possibly rituximab or obinutuzumab) in adults with B-cell lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma. The goal is to see if the combination is safe …
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for hard-to-treat blood cancers: phase 3 trial pits NX-5948 against standard therapy
Disease control Not yet recruitingThis study compares two drugs, NX-5948 and pirtobrutinib, in about 620 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding after prior treatment with a BTK inhibitor. The main goal is to see which drug…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New CAR t therapy targets two proteins to fight blood cancers
Disease control Not yet recruitingThis early-phase trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD20) on B cell cancer cells. It is for adults with B cell leukemia or lymphoma who have run out of standard options, including commercial CAR T cells. The main goal is to check safe…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New pill aims to keep lymphoma away after CAR-T
Disease control Not yet recruitingThis study tests whether taking zanubrutinib (a targeted cancer pill) for two years after CAR-T cell therapy can help keep non-Hodgkin B-cell lymphoma from coming back. About 40 adults whose cancer responded to CAR-T will receive the drug. The main goal is to see how many remain …
Matched conditions: B-CELL LYMPHOMA
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Engineered immune cells take on tough blood cancers
Disease control Not yet recruitingThis early-stage trial tests a personalized cell therapy called CD19/22 CAR-T cells in 17 adults with relapsed or refractory acute lymphoblastic leukemia or B-cell lymphoma. Patients receive their own immune cells that have been reprogrammed to target and kill cancer cells. The s…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology • Aim: Disease control
Last updated Jun 26, 2026 14:45 UTC